# PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

> **NCT04544111** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Thyroid Cancer
- Thyroid Cancer, Follicular
- Papillary Thyroid Cancer
- Follicular Thyroid Cancer
- Hurthle Cell Tumor
- Poorly Differentiated Thyroid Gland Carcinoma
- Hurthle Cell Thyroid Neoplasia

## Interventions

- **DRUG:** Trametinib
- **DRUG:** Dabrafenib
- **DRUG:** PDR001

## Key facts

- **NCT ID:** NCT04544111
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-02
- **Primary completion:** 2026-09-02
- **Final completion:** 2026-09-02
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04544111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04544111, "PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04544111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*